Eli Lilly and Novo Nordisk are competing over $150B in future obesity drug sales. But behind the ad lawsuits and pipeline headlines, there’s a quieter battle: who gets to hire and keep the scientists, engineers, and executives who actually build this market.
The numbers tell two very different stories right now:
๐๐ถ๐น๐น๐ ๐ถ๐ ๐ถ๐ป ๐ณ๐๐น๐น ๐ด๐ฟ๐ผ๐๐๐ต ๐บ๐ผ๐ฑ๐ฒ
$27B pledged for four new U.S. manufacturing sites – 3,000 permanent jobs for engineers, scientists, and lab technicians, plus ~10,000 construction jobs
$50B+ in U.S. capital investment since 2020, $21B+ of it in Indiana alone
A new $4.5B injection into its Lebanon, Indiana LEAP campus, home to the Lilly Medicine Foundry (~400 new science/engineering roles)
A Boston R&D hub (Lilly Seaport Innovation Center) built specifically around RNA/DNA therapeutics talent
CEO David Ricks was pharma’s highest-paid CEO in 2025 at $36.7M – a 26% raise
๐ก๐ผ๐๐ผ ๐ก๐ผ๐ฟ๐ฑ๐ถ๐๐ธ ๐ถ๐ ๐ฐ๐ผ๐ป๐๐ฟ๐ฎ๐ฐ๐๐ถ๐ป๐ด ๐ฎ๐ป๐ฑ ๐ฟ๐ฒ๐ฏ๐๐ถ๐น๐ฑ๐ถ๐ป๐ด
Cut 9,000 jobs (11% of its workforce) in 2025 as Lilly ate into its obesity market lead
New CEO Mike Doustdar’s first major move: hiring freezes in non-critical areas, then a five-day return-to-office mandate to “move faster”
Boardroom churn – the Novo Nordisk Foundation moved to retake board control, several independent directors quit, and a candidate (Pfizer’s former R&D chief Mikael Dolsten) withdrew from a board race
Chief Medical Officer Dr. Zachary Roberts departed to become CEO of Allogene Therapeutics
Former CEO Lars Fruergaard Jรธrgensen was ousted after Novo stock fell ~52% from its peak – still exiting with ~$19.5M in pay
๐ช๐ต๐ ๐๐ต๐ฒ ๐ฐ๐ผ๐บ๐ฝ๐ฒ๐๐ถ๐๐ถ๐ผ๐ป ๐ผ๐๐ฒ๐ฟ ๐ฝ๐ฒ๐ผ๐ฝ๐น๐ฒ ๐บ๐ฎ๐๐๐ฒ๐ฟ๐ ๐๐ผ ๐บ๐๐ฐ๐ต
Deloitte data shows obesity treatments have overtaken oncology as pharma’s biggest contributor to late-stage pipeline value – the first time in 16 years oncology hasn’t led. That means metabolic-disease scientists are now the most in-demand specialists in the industry, and it’s not just a two-horse race: Viking Therapeutics, Kailera, Pfizer, and a wave of Chinese biotechs are all competing for the same limited pool of GLP-1 expertise.
Even the drugs themselves have become a recruiting tool. Nearly a third of employees say they’d switch jobs for GLP-1 coverage, and employers increasingly frame it as a retention lever, not just a benefit line item.
The historical irony: Novo Nordisk’s own predecessor companies spent decades poaching researchers from each other before merging to stop competing for the same talent pool internally. Now Novo finds itself on the losing end of a very similar dynamic – this time with Lilly on the other side.
Lilly is building. Novo is rebuilding. And the scientists, engineers, and executives who choose between them may shape who ultimately leads the GLP-1 race.
